FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis

cafead

Administrator
Staff member
  • cafead   Sep 18, 2024 at 11:22: PM
via The FDA approved AstraZeneca’s Fasenra (benralizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), according to a news release published today.

article source